Continuation of The Collaborative Islet Transplantation Registry (CITR)

协作胰岛移植登记处 (CITR) 的延续

• 批准号: 10704577
• 负责人: Elizabeth Holly Payne
• 金额: $ 70.37万
• 依托单位: THE EMMES COMPANY, LLC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10704577
• 关键词: Address; Allogenic; Autologous; Biometry; Case Report Form; Cell physiology; Clinical; Clinical Treatment; Collaborations; Collection; Communication; Communities; Complex; Data; Data Collection; Data Reporting; Development; Diabetes Mellitus; Ensure; Funding; Goals; Health; Human; Hypoglycemia; Insulin-Dependent Diabetes Mellitus; International; Islet Cell; Islets of Langerhans; Islets of Langerhans Transplantation; Journals; Knowledge; Lead; Leadership; Manuscripts; Methods; National Institute of Diabetes and Digestive and Kidney Diseases; Outcome; Pancreatectomy; Peer Review; Persons; Positioning Attribute; Publications; Refractory; Registries; Research Personnel; Resolution; Running; Safety; Secure; Security; Site; Source; Statistical Data Interpretation; Therapeutic; Transplantation; U-Series Cooperative Agreements; Validation; Work; beta cell replacement; cell replacement therapy; data exchange; data registry; experience; flexibility; follow-up; health assessment; meetings; multidisciplinary; new technology; posters; programs; quality assurance; response; success; transplant registry

PROJECT SUMMARY This application, in response to RFA-DK-21-013, describes a comprehensive Data and Statistical Coordinating Center (DSCC) for the Collaborative Islet Transplant Registry (CITR) for 2022-2027. Continuing from 2017-2021 as the CITR-DSCC, Emmes continues to collaborate with the NIDDK Program Office, the Oversight Committee, and the CITR investigators to support the established CITR Registry. The registry includes allogeneic and autologous pancreatic islet transplantation, as well as any other beta cell replacement therapies that should be followed for efficacy and safety in the resolution of refractory glycemic lability marked by severe hypoglycemic episodes in persons with Type 1 diabetes or lacking pancreatic islets for any reason including therapeutic pancreatectomy or any loss of islet cell function. For more details, please see the Specific Aims section.

项目总结